Case Report Open Access
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 26, 2019; 7(20): 3310-3315
Published online Oct 26, 2019. doi: 10.12998/wjcc.v7.i20.3310
Recognizable type of pituitary, heart, kidney and skeletal dysplasia mostly caused by SEMA3A mutation: A case report
Fang Hu, Liao Sun, Department of Endocrinology and Metabolism, Fifth Affiliated Hospital Sun Yat-Sen University, Sun Yat-Sen University, Zhuhai 519000, Guangdong Province, China
ORCID number: Fang Hu (0000-0002-6610-6495); Liao Sun (0000-0002-1798-0944).
Author contributions: All authors collected and analyzed the patient’s clinical data; Hu F wrote the manuscript and Sun L revised the manuscript.
Informed consent statement: The patient provided written informed consent to the publication of this case report.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Liao Sun, PhD, Chief Doctor, Department of Endocrinology and Metabolism, Fifth Affiliated Hospital Sun Yat-Sen University, Sun Yat-Sen University, Meihuadong Road 52, Zhuhai 519000, Guangdong Province, China. sunliao@mail.sysu.edu.cn
Telephone: +86-756-2528741 Fax: +86-756-2528741
Received: June 25, 2019
Peer-review started: June 27, 2019
First decision: July 31, 2019
Revised: August 29, 2019
Accepted: September 11, 2019
Article in press: September 11, 2019
Published online: October 26, 2019
Processing time: 123 Days and 14.4 Hours

Abstract
BACKGROUND

The SEMA3A gene, which is located at 7q21.11, is involved in hypothalamic neuron migration, heart development, kidney development, and skeleton metabolism. Mutation of the SEMA3A gene is associated with Kallmann syndrome 16 with or without a normal sense of smell. In addition, two case reports showed that mutation of the SEMA3A gene could cause short stature, low gonadotropin, hypogonadism, thoracic deformity, a high scapula, rib and lower limb deformity, facial deformity (long face, epicanthic folds, backwards ears), and arterial malformation.

CASE SUMMARY

We reported the case of a 26-year-old Chinese man who was admitted because of short stature. Physical examination showed that he had many abnormal symptoms, including a short neck, facial moles, knee valgus, transverse palm, continuous grade 5/6 murmurs in the pulmonary auscultation area, no whiskers, or pubic hair, no Adam’s apple, short penis and cryptorchidism. Radiological examination showed pituitary, gonad, heart, kidney and skeletal dysplasia. The laboratory tests revealed low growth hormone, luteinizing hormone, follicle-stimulating hormone, testosterone and estrogen. Clinical whole-exome detection showed that our patient, unlike previously reported patients, has a new SEMA3A gene mutation (c.950A>G). Now, his height has increased by 3 cm. In addition, he has a good appetite and reduced subcutaneous fat over 3 mo of recombinant human growth hormone injections therapy. Unfortunately, he refuses further treatment about gonad.

CONCLUSION

Patients who come to a hospital because of their short stature must undergo gene detection if they have other simultaneous abnormal phenotypes.

Key Words: Pituitary dysplasia; Heart dysplasia; Kidney dysplasia; Short stature; Cryptorchidism; SEMA3A; Case report

Core tip: The SEMA3A gene is involved in hypothalamic neuron migration, heart development, kidney development, and skeleton metabolism. Mutation of the SEMA3A gene was associated with short stature, low gonadotropin, hypogonadism, thoracic deformity, a high scapula, rib and lower limb deformity, facial deformity (long face, epicanthic folds, backwards ears), and arterial malformation in cases reported before. Here, we report a patient who exhibited pituitary, heart, kidney and skeletal dysplasia caused by new mutation of the SEMA3A gene (c.950A>G).



INTRODUCTION

The SEMA3A gene is located at 7q21.11 and has a length of 496947 bp. SEMA3A is a member of the semaphorin family and encodes a protein with an Ig-like C2-type (immunoglobulin-like) domain, a PSI domain and a sema domain called semaphorin-3A. Semaphorin-3A is important in the development and migration of hypothalamic neurons. It is secreted by neurons and their surrounding tissue and guides migrating cells to their correct destination following very precise paths, sends out axons, and reacts to specific chemical environments. In addition, as a dual regulator of osteoclasts and osteoblasts, semaphorin 3A is involved in the balance of bone homeostasis by the SEMA3A/NRP1 axis and the Wnt/β-catenin signaling pathway[1]. Semaphorins are needed in kidney development because they regulate ureteric bud branching, vascular morphogenesis, and podocyte-endothelial crosstalk[2]. SEMA3A-knockout mice exhibited an abnormal electrocardiograph pattern and were prone to ventricular arrhythmias and sudden cardiac death[3]. Therefore, SEMA3A is important in maintaining normal heart function.

SEMA3A mutations often appear in patients with Kallmann syndrome[4]. In addition, patients with mutation of the SEMA3A gene exhibiting short stature, low gonadotropin, hypogonadism, thoracic deformity, high scapula, rib and lower limb deformity, facial deformity (long face, epicanthic folds, backwards ears), arterial malformation, and a normal sense of smell have been reported[5]. We report a patient who exhibited pituitary, heart, kidney and skeletal dysplasia caused by new mutation of the SEMA3A gene.

CASE PRESENTATION
Chief complaints

A 26-year-old Chinese man complained of short stature.

History of present illness

The 26-year-old patient, who was his parents’ first child, was 50 cm in length and weighed 3.3 kg when he was born at 40 wk of gestation. His growth rate gradually slowed down beginning at the age of 12. Now, he is 133 cm tall (< -2.0 SD) with a 65 cm long upper half and 68 cm long lower half and weighs 35 kg (< -2.0 SD), with 130 cm finger spacing.

History of past illness

No disease in the past.

Personal and family history

His sister is of normal height and physical development. The patient was born normally without ischemia and hypoxia. His mother’s height is 156 cm, and his father’s height is 155 cm. The predicted height of the boy was calculated to be below the mid-parental height of 162 cm.

Physical examination upon admission

His abnormal symptoms are a short neck; facial moles; knee valgus; transverse palm; continuous grade 5/6 murmurs in the pulmonary auscultation area; no whiskers, or pubic hair; no Adam’s apple; a penis length of approximately 2 cm; a penis circumference of 3 cm and cryptorchidism (Figure 1A).

Figure 1
Figure 1 Clinical findings and radiographic abnormalities in a patient with a heterozygous SEMA3A gene mutation (c. 950A>G). The patient was 26 years old. A: He exhibited a short neck; facial moles; knee valgus; transverse palm; continuous grade 5/6 murmurs in the pulmonary auscultation area; no whiskers,or pubic hair; no Adam’s apple; short penis and cryptorchidism; B: Pituitary magnetic resonance imaging (MRI) showed pituitary dysplasia; C, D: Pelvic MRI showed the following: (1) Pelvic genitourinary dysplasia, in which (1) The prostate and bilateral seminal vesicles were not clearly shown; (2) The bilateral groin had soft tissue nodules and testicular hypoplasia; and (3) Penile dysplasia was observed, and (B) a pelvic bone that was not closed; E: Left wrist orthotopic X-ray (bone age of 15 years).
Laboratory examinations

The patient’s liver and kidney function, cortisol rhythm and thyroid function were normal. He completely lacked growth hormone, as shown through hypoglycemia challenge, a levodopa test and IGF-1 determination. His 25-hydroxyvitamin D was 11.3 ng/mL (low). Sex hormone assessment showed that the levels of luteinizing hormone (LH), follicle-stimulating hormone, testosterone and estrogen were all below normal. The peak LH level in a GnRH excitation test was 1.92 nmol/L (< 5 nmol/L). The peak testosterone level in a delayed human chorionic gonadotropin excitation test was 0.91 ng/mL (< 10 ng/mL). Conventional karyotyping after GTG-banding at a 500-band resolution showed a normal male karyotype (46, XY). Chromosomal microarray analysis showed no abnormalities.

Written informed consent for clinical whole-exome detection was obtained from the patient. All of the 3583 genes identified by the OMIM database were identified by high-throughput sequencing. Clinical whole-exome detection was offered by BGI in Shenzhen, Guangdong Province.

The results of clinical whole-exome detection are shown in Table 1. The diseases related to the LHCGR, HSPG2, and PKDIL1 genes were autosomal recessive. ANCA gene-related exfoliative osteochondritis, short statue, early onset arthritis and vertebral hypoplasia exhibited autosomal dominant inheritance. SEMA3A gene-related hypogonadotropic hypogonadism with or without olfactory loss exhibited autosomal dominant inheritance.

Table 1 Clinical whole-exome detection results.
GeneSequenceNucleotide change/mutationAmino acid changeGene subregionHeterozygousChromosome locationVariant type
ACANNM_013227.3c.6798G>Ap.Pro22666=EX12HeterozygousChr15: 89402614VUS
LHCGRNM_000233.3c.911G>Ap.Cys304TyrEX10HeterozygousChr2: 48921399VUS
HSPG2NM_005529.5c.1216C>Tp.Pro406SerEX11HeterozygousChr1: 22211645VUS
PKD1L1NM_138295.3c.2842T>Gp.Phe948ValEX18HeterozygousChr7: 47925647VUS
SEMA3ANM_006080.2c.950A>Gp.Lys317ArgEX9HeterozygousChr7: 83640383VUS
Imaging examinations

His bone age was 15 years old (Figure 1E). Dual-energy X-ray bone density assessment showed that the T (lumbar spine) was -5.3 SD below the mean and T (left hip joint) was -2.4 SD below the mean. Pelvic magnetic resonance imaging (MRI) (Figure 1C, D) showed the following: (A) Pelvic genitourinary dysplasia, in which (1) The prostate and bilateral seminal vesicles were not clearly shown; (2) The bilateral groin had soft tissue nodules and testicular hypoplasia; and (3) Penile dysplasia was observed; and (B) A pelvic bone that was not closed. In addition, abdominal ultrasound suggested left renal hypoplasia. Cardiac ultrasound suggested aortic dysplasia with moderate reflux. Pituitary MRI suggested pituitary dysplasia (Figure 1B).

FINAL DIAGNOSIS

LHCGR, HSPG2, PKDIL1, ANCA and SEMA3A are all heterozygous mutation. So ANCA and SEMA3A gene mutations might be related to the symptom shown by our patient. However, ANCA gene mutation could not cause the previously reported gonadal and cardiac dysplasia. Therefore, we focused on SEMA3A as the pathogenic gene. So final diagnosis is SEMA3A mutation, growth hormone deficiency, short stature, hypogonadotropic hypogonadism, heart dysplasia, kidney dysplasia and skeletal dysplasia.

TREATMENT

The patient was treated with recombinant human growth hormone injections (0.15 U/kg, GenSci, Changchun, Jilin Province). He refuses further treatment about gonad.

OUTCOME AND FOLLOW-UP

Now, his height has increased by 3 cm. In addition, he has a good appetite and reduced subcutaneous fat over 3 mo of recombinant human growth hormone injections therapy. We will continue to observe his height, bone density and gonads.

DISCUSSION

Two similar case reports have been published before. The SEMA3A genotype of the first case reported in 2013 included a compound-heterozygous de novo in-frame mutation in exon 9 (c.945_949delinsTACATCTTCTAATG; p. Phe316_Lys317-delinsThrSerSerAsnGlu), a 150-kb deletion, the retention of intron 8, and a premature stop codon after 348 amino acids[6]. The SEMA3A genotype of the second case reported in 2018 included a homozygous c.607C>T [p.(Arg203*)] mutation in exon 6[5]. All patients not only exhibited short statue, facial dysmorphism and skeletal system anomalies but also had cardiovascular, urogenital, hearing, olfactory, visual, motor development and cognitive development defects. There were some differences between our patient and the two patients presented previously (Table 2). First, the SEMA3A genotype in our patient is c.950A>G. Second, examination of our patient showed a complete lack of growth hormone, but this was not mentioned during the examination of the other two patients. Our patient’s short statue was perhaps caused by not only a lack of growth hormone but also vitamin D deficiency. Third, our patient has normal cognitive function and works in an electrical factory. Finally, he has kidney hypoplasia. Semaphorins are needed in kidney development because they regulate ureteric bud branching, vascular morphogenesis, and podocyte-endothelial crosstalk[5]. Thus, SEMA3A gene mutation might result in kidney hypoplasia. In contrast, SEMA3A overexpression could promote foot process effacement, glomerular basement lamination, and endothelial damage in vivo and disrupt autonomous podocyte shape by downregulating nephrin and inhibiting αvβ3 integrin[7]. Excess SEMA3A also promoted severe diabetic nephropathy[8]. No genes related to pituitary dysplasia were discovered in whole gene exome detection. Pituitary dysplasia might occur mainly because of defective hypothalamic neurons.

Table 2 Summary of patients’ clinical presentations and comparison to the published patients.
EthnicityPatient 1
Patient 2
Patient 3
AsianTurkishSouthern German
Mutationc.950A>G (p.Lys317Arg) in exon 9, heterozygousc.607C>T [p.(Arg203*)] in exon 6, homozygousc.945_949delinsTACATCTTCTAATG; p.Phe316_Lys317-; delinsThrSerSerAsnGlu in exon 9, de novo, in-frame; 150-kb deletion, intron-8 retention, premature stop codon after 348; amino acids, compound-heterozygous
GenderMaleMaleMale
Gestational age (wk)404137
Age at examination2686
Birth weight and lengthWeight: unknown; Length: unknownWeight: 3720 g (P50-P75; 0.19 SDS); Length: 50 cm (P10-25; -1.25 SDS)Weight: 2910 g (P25-P50; -0.92 SDS); Length: 48 cm (P10-P25; -0.43 SDS)
Mother’s and father’s heights156 cm, 155 cm154 cm, 174 cm159 cm, 174 cm
Short statue+++
Facial dysmorphismFacial moles, transverse palmLong face; epicanthic folds; mildly low-set, backwards; rotated ear; bilateral retrolobular notches; long philtrumLong face; epicanthic folds; mildly low-set, backwards, rotated ear; dolichocephaly; prominent forehead; broad nasal root; rounded nasal tip; long philtrum; thin lips; high palate; crossbite with crowded teeth
Skeletal systemShort neck, knee valgusHigh-positioned scapulae, lateral clavicle hook, restricted mobility of the shoulder joints, arched rib deformation, mild upper thoracic; scoliosis, widely spaced nipples, camptodactyly of the second and third fingers, flexion contracture of the right knee with patellar luxationSloping shoulders, broad and asymmetric thorax, flattened vertebrae in the upper thoracic region, mild funnel chest, kyphosis, hyperlordosis, widely spaced nipples, camptodactyly, of the third left finger,relatively large first toe
CardiovascularAortic dysplasia with moderate refluxArteria lusoriaPatent foramen ovale, nearly closed with 6 yr
UrogenitalNo prostate, bilateral seminal vesicles, testicular hypoplasia and cryptorchidism, micropenisMicropenisMicropenis
HearingNormalMild conductive hearing impairmentSusceptible to upper airway and middle ear infections until 2 yr of age
OlfactionNormalNormalNormal
VisionNormalMyopiaHyperopia
Motor developmentNormalDelayed, walking independently at 3.8 yrDelayed, walking independently at 21 mo
Cognitive developmentNormalReduced performance and verbal score with a full scale IQ of 55 (at 6 yr)Average performance and full scale IQ, verbal IQ in the lower average; range (at 5 yr)
KidneyHypoplasiaNormalNormal
Growth hormoneLackingUnknownUnknown
Sex hormoneLackingUnknownUnknown
CONCLUSION

At present, short stature gets more and more attention. But we should make a clear diagnosis through gene detection if they have other simultaneous abnormal phenotypes.

Footnotes

Manuscript source: Unsolicited manuscript

Specialty type: Medicine, Research and Experimental

Country of origin: China

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Papachristou G S-Editor: Dou Y L-Editor: Ma JY E-Editor: Qi LL

References
1.  Tse MT. Bone diseases: SEMA3A strikes a balance in bone homeostasis. Nat Rev Drug Discov. 2012;11:442.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 9]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
2.  Reidy K, Tufro A. Semaphorins in kidney development and disease: modulators of ureteric bud branching, vascular morphogenesis, and podocyte-endothelial crosstalk. Pediatr Nephrol. 2011;26:1407-1412.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 62]  [Cited by in F6Publishing: 54]  [Article Influence: 4.2]  [Reference Citation Analysis (0)]
3.  Boczek N J, Ye D, Johnson E K, Wang W, Crotti L, Tester D J, Dagradi F, Mizusawa Y, Torchio M, Alders M, Giudicessi J R, Wilde A A M, Schwartz P J, Nerbonne J M, Ackerman M J. Characterization of SEMA3A-Encoded Semaphorin as a Naturally Occurring Kv 4.3 Protein Inhibitor and its Contribution to Brugada Syndrome. Circ Res. 2014;115:460-469.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 47]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
4.  Hanchate NK, Giacobini P, Lhuillier P, Parkash J, Espy C, Fouveaut C, Leroy C, Baron S, Campagne C, Vanacker C, Collier F, Cruaud C, Meyer V, García-Piñero A, Dewailly D, Cortet-Rudelli C, Gersak K, Metz C, Chabrier G, Pugeat M, Young J, Hardelin JP, Prevot V, Dodé C. SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome. PLoS Genet. 2012;8:e1002896.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 149]  [Cited by in F6Publishing: 143]  [Article Influence: 11.9]  [Reference Citation Analysis (0)]
5.  Baumann M, Steichen-Gersdorf E, Krabichler B, Müller T, Janecke AR. A recognizable type of syndromic short stature with arthrogryposis caused by bi-allelic SEMA3A loss-of-function variants. Clin Genet. 2017;92:86-90.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
6.  Hofmann K, Zweier M, Sticht H, Zweier C, Wittmann W, Hoyer J, Uebe S, van Haeringen A, Thiel CT, Ekici AB, Reis A, Rauch A. Biallelic SEMA3A defects cause a novel type of syndromic short stature. Am J Med Genet A. 2013;161A:2880-2889.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 9]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
7.  Mohamed R, Ranganathan P, Jayakumar C, Nauta FL, Gansevoort RT, Weintraub NL, Brands M, Ramesh G. Urinary semaphorin 3A correlates with diabetic proteinuria and mediates diabetic nephropathy and associated inflammation in mice. J Mol Med (Berl). 2014;92:1245-1256.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 20]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
8.  Liu DM, Lu N, Zhao L, Zhang MJ, Tao B, Xuan Y, Sun LH, Zhao HY, Wang WQ, Liu JM, Ning G. Serum Sema3A is in a weak positive association with bone formation marker osteocalcin but not related to bone mineral densities in postmenopausal women. J Clin Endocrinol Metab. 2014;99:E2504-E2509.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 12]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]